Amgen Inc (AMGN): R&D Expense
$7.27B
Year ended 2025-12-31
$7.63B
Trailing 12 months to 2026-06-30
+17.9%
3-year compound annual growth
+11.6%
5-year compound annual growth
+6.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.27B | +21.9% | 2026-02-13, From 2025-01-01 |
| 2024-12-31 | $5.96B | +24.7% | 2026-02-13, From 2024-01-01 |
| 2023-12-31 | $4.78B | +7.9% | 2026-02-13, From 2023-01-01 |
| 2022-12-31 | $4.43B | -8.0% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $4.82B | +14.5% | 2024-02-14, From 2021-01-01 |
| 2020-12-31 | $4.21B | +2.2% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $4.12B | +10.1% | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $3.74B | +4.9% | 2021-02-09, From 2018-01-01 |
| 2017-12-31 | $3.56B | -7.2% | 2020-02-12, From 2017-01-01 |
| 2016-12-31 | $3.84B | -5.7% | 2019-02-13, From 2016-01-01 |
| 2015-12-31 | $4.07B | -5.3% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $4.30B | +5.2% | 2017-02-14, From 2014-01-01 |
| 2013-12-31 | $4.08B | +20.8% | 2016-02-16, From 2013-01-01 |
| 2012-12-31 | $3.38B | +6.7% | 2015-02-19, From 2012-01-01 |
| 2011-12-31 | $3.17B | +9.4% | 2014-02-24, From 2011-01-01 |
| 2010-12-31 | $2.89B | +1.0% | 2013-02-27, From 2010-01-01 |
| 2009-12-31 | $2.86B | -5.5% | 2012-02-29, From 2009-01-01 |
| 2008-12-31 | $3.03B | -7.2% | 2011-02-25, From 2008-01-01 |
| 2007-12-31 | $3.27B | n/a | 2010-03-01, From 2007-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $187.52M | -3.1% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.13B | -31.1% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
Compare AMGN, GILD, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗